About: Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 February 1993

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в лютому 1993 (uk) article scientifique publié en 1993 (fr) im Februar 1993 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en febreru de 1993 (ast) artikull shkencor i botuar më 01 shkurt 1993 (sq) scientific article published on 01 February 1993 (en)
publication date	wds:Q70549000-D8126D33-8E65-4B91-9019-FC1F3AAD2452
publication date	1993-02-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q70549000-D92B8ACB-3B7B-4CA5-B6C8-02449CFA2242
language of work or name	English
author name string	wds:Q70549000-0679B7A7-B234-485F-902F-E5E14D125C7B wds:Q70549000-0D7ADFED-6846-454C-9EFB-3D82DC5238E5 wds:Q70549000-1050B4A4-440C-4857-8EBE-ABD0138E3611 wds:Q70549000-1D115C44-8F62-43F9-B272-6D8A8345E157 wds:Q70549000-208FEB3E-BC0D-4683-A4DA-1E905FD6A5FD wds:Q70549000-5F4B19A2-DAA6-4E14-909A-327F94959E1A wds:Q70549000-D42474D5-7528-4A2B-A671-9EC60DBC33DC
author name string	Kishimoto T Tsuchiya M Sato K Saldanha J Koishihara Y Ohsugi Y Bendig MM
rdfs:label	Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth (en) Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth (nl) Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth (sq)
skos:prefLabel	Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth (en) Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth (nl) Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth (sq)
name	Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth (en) Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth (nl) Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth (sq)
title	wds:Q70549000-16F63A9E-B23A-4261-9EE4-70537183B74D
title	Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth (en)
page(s)	wds:Q70549000-9424B709-E5F2-478D-BE60-8B393C135181
page(s)	851-856
instance of	wds:Q70549000-FB8566EA-F1FA-43C1-841C-D8DE21B3F5F4
instance of	scholarly article
PubMed ID	wds:Q70549000-39C560CC-F70E-42E5-8F46-81B9A6474336
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8428365
PubMed ID	8428365
published in	wds:Q70549000-89B56459-1737-4604-B060-8272AB4B4DD0
published in	Cancer Research
issue	wds:Q70549000-5CC1EBE6-EC22-4EF2-A7F0-F6674081148E
volume	wds:Q70549000-A085B471-CAF2-4E67-A05F-BEEF1BEEE9DC
issue	4
volume	53
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q70549000
is cites work of	Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab Interleukin 6 and rheumatoid arthritis Multiple myeloma: increasing evidence for a multistep transformation process Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularization The paradigm of IL-6: from basic science to medicine Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibi Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody In vitro and in vivo antitumor activity of a chimeric anti-CD19 antibody Anti-interleukin 6 receptor antibody treatment in rheumatic disease Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice Interleukin-6--a key regulator of colorectal cancer development. Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130. IL-6 in inflammation, immunity, and disease Treatment of Crohn's disease with anti-IL-6 receptor antibody. High circulating levels of biologically inactive IL-6/SIL-6 receptor complexes in systemic juvenile idiopathic arthritis: evidence for serum factors interfering with the binding to gp130 IL-6 as a keystone cytokine in health and disease Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. IL-6 signaling by STAT3 participates in the change from hyperplasia to neoplasia in NRP-152 and NRP-154 rat prostatic epithelial cells Anti-proliferative action of IL-6R-targeted antibody tocilizumab for non-small cell lung cancer cells. Successful treatment of massive intractable pericardial effusion in a patient with systemic lupus erythematosus with tocilizumab Early intervention in the treatment of rheumatoid arthritis: focus on tocilizumab Interleukin-6: discovery of a pleiotropic cytokine Profiles of Basal and stimulated receptor signaling networks predict drug response in breast cancer lines Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences Tocilizumab in pediatric rheumatology: the clinical experience IL-6: from laboratory to bedside Systemic arthritis in children: a review of clinical presentation and treatment Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis Interleukin-6 and rheumatic diseases Recommendations of the German rheumatology society on the use of tocilizumab in rheumatoid arthritis Tocilizumab. Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors Involvement of NF-κB/IL-6 Pathway in the Processing of Colorectal Carcinogenesis in Colitis Mice Structural pathways of cytokines may illuminate their roles in regulation of cancer development and immunotherapy. Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System. Interleukin-6-induced proliferation of human myeloma cells associated with CD45 molecules Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis The IL-6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B-cell lymphoma Effects of tumor necrosis factor inhibitors and tocilizumab on the glycosylated hemoglobin levels in patients with rheumatoid arthritis; an observational study. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis Interleukin (IL-6) Immunotherapy Novel genetically-humanized mouse model established to evaluate efficacy of therapeutic agents to human interleukin-6 receptor Clinical efficacy of tocilizumab in patients with active rheumatoid arthritis in real clinical practice Active immunization with Tocilizumab mimotopes induces specific immune responses Management of rheumatoid arthritis in People's Republic of China - focus on tocilizumab and patient considerations

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software